NCT01326481View on ClinicalTrials.gov

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Metastatic Breast Cancer
Interventions
DRUG

TRC105

IV

DRUG

Capecitabine

oral

Trial Locations (2)

14201

Roswell Park Cancer Institute, Buffalo

35294-3300

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Roswell Park Cancer Institute

OTHER

collaborator

United States Department of Defense

FED

lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT01326481 - Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter